TherapeuticsMD (TXMD) Return on Capital Employed (2011 - 2026)
TherapeuticsMD's (TXMD) quarterly Return on Capital Employed came in at 11.72% in Q1 2026, up 562.0% YoY from 1.77% in Q1 2025, and up 10.92% on a QoQ basis from 13.15% in Q4 2025.
TherapeuticsMD (TXMD) Return on Capital Employed (2011 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 15 years of Return on Capital Employed data on file, last reported at 11.72% in Q1 2026.
- Quarterly Return on Capital Employed rose 562.0% year-over-year to 11.72% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.72% (up 562.0% YoY) and the FY2025 annual result came in at 13.12%, up 390.0% from the prior year.
- Return on Capital Employed improved to 11.72% in Q1 2026, from 13.15% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 446.57% in Q2 2022 to a low of 21.28% in Q4 2023.
- A 5-year average of 50.06% and a median of 11.16% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 52966 bps — and 2023, when it sank 37849 bps.
- Tracing TXMD's Return on Capital Employed over 5 years: stood at 1.82% in 2022, then sank by 1268 bps to 21.28% in 2023, then gained by 21 bps to 16.8% in 2024, then increased by 22 bps to 13.15% in 2025, then increased by 11 bps to 11.72% in 2026.
- The last three Return on Capital Employed figures came in at 11.72% (Q1 2026), 13.15% (Q4 2025), and 10.37% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.43 Bn | 43.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.65 Bn | 40.00 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 32.52 Bn | 30.85 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 19.00 Bn | 18.12 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.03 Bn | 11.50 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | TherapeuticsMD | 23.78 Mn | 14.60 Mn | - | -12.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.14% |
| Mar 31, 2026 | -11.72% |
| Dec 31, 2025 | -13.15% |
| Sep 30, 2025 | -10.37% |
| Jun 30, 2025 | -11.16% |
| Mar 31, 2025 | -17.33% |
| Dec 31, 2024 | -16.80% |
| Sep 30, 2024 | -19.71% |
| Jun 30, 2024 | -20.73% |
| Mar 31, 2024 | -19.32% |
| Dec 31, 2023 | -21.28% |
| Sep 30, 2023 | 110.51% |
| Jun 30, 2023 | 68.08% |
| Mar 31, 2023 | 29.45% |
| Dec 31, 2022 | 1.82% |
| Sep 30, 2022 | 242.95% |
| Jun 30, 2022 | 446.57% |
| Mar 31, 2022 | 113.19% |
| Dec 31, 2021 | 220.66% |
| Sep 30, 2021 | -112.22% |